X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
LB-100 is a PP2A inhibitor which is being evaluated in phase 1/2 clinical trials in combination with Dostarlimab-gxly for the treatment of ovarian clear cell carcinoma.
Lead Product(s): LB-100,Dostarlimab
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2024
Details:
Under the terms of the license agreement, LIXTE will allow LB-100, which is a PP2A inhibitor with Dostarlimab for the treatment of Ovarian Clear Cell Carcinoma.
Lead Product(s): LB-100,Dostarlimab
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute of Neurological Disorders and Stroke
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 26, 2024
Details:
LB-100 is a PP2A inhibitor which is being evaluated in phase 1/2 clinical trials in combination with Dostarlimab-gxly for the treatment of ovarian clear cell carcinoma.
Lead Product(s): LB-100,Dostarlimab
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2024
Details:
The expanded collaboration aims to study drug synergies of LIXTE’s lead clinical compound, LB-100, an inhibitor of the PP2A phosphatase, with immunotherapy in various cancers.
Lead Product(s): LB-100,Atezolizumab
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Netherlands Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration October 16, 2023
Details:
LB-100 is an inhibitor of PP2A, added to dostarlimab significantly increase the effectiveness of PD-1 immune-checkpoint blockade by activating cytotoxic T cells and CAR-T cells. It is being investegated for Clear-Cell Ovarian Cancer.
Lead Product(s): LB-100,Dostarlimab
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2023
Details:
The company intends to use the net proceeds for further clinical development of its first-in-class lead clinical PP2A inhibitor, LB-100, being developed in patients with low and intermediate-1 risk Myelodysplastic Syndrome (MDS).
Lead Product(s): LB-100
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $3.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 20, 2023
Details:
LB-100 is an inhibitor of PP2A, added to doxorubicin significantly increase the effectiveness of PD-1 immune-checkpoint blockade by activating cytotoxic T cells and CAR-T cells. It is being investegated for advanced soft tissue sarcoma.
Lead Product(s): LB-100,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2023
Details:
LB-100 is an inhibitor of PP2A, added to doxorubicin significantly increase the effectiveness of PD-1 immune-checkpoint blockade by activating cytotoxic T cells and CAR-T cells. It is being investegated for advanced soft tissue sarcoma.
Lead Product(s): LB-100,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2023
Details:
LIXTE’s first-in-class protein phosphatase 2A (PP2A) inhibitor LB-100 with a standard regimen for previously untreated, extensive stage disease small cell lung cancer (ED-SCLC).
Lead Product(s): LB-100,Atezolizumab,Carboplatin
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
LB-100, an inhibitor of PP2A, significantly increase the effectiveness of PD-1 immune-checkpoint blockade by activating cytotoxic T cells and CAR-T cells. It has shown significant tumor shrinkage and the arrest of tumor progression in patients with advancing cancers.
Lead Product(s): LB-100,Atezolizumab,Carboplatin
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
